| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,890,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
2,615,875 |
Avg
Vol: |
1,192,496 |
| 52
Week Range: |
$7.07 - $7.07 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rieflin William Jl |
President |
• – – |
2008-12-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
25,000 |
75,000 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-12-01 |
4 |
AS |
$28.88 |
$35,945 |
I/I |
(1,200) |
117,053 |
|
- |
|
| Rieflin William Jl |
President |
• – – |
2008-11-10 |
4 |
OE |
$15.00 |
$283,305 |
I/I |
18,887 |
149,608 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-11-03 |
4 |
AS |
$41.12 |
$42,015 |
D/D |
(1,000) |
10,198 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-11-03 |
4 |
OE |
$1.50 |
$1,500 |
D/D |
1,000 |
11,198 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-11-03 |
4 |
AS |
$41.12 |
$113,537 |
I/I |
(2,700) |
118,553 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-11-03 |
4 |
AS |
$41.12 |
$12,584 |
I/I |
(300) |
118,253 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-10-01 |
4 |
AS |
$48.82 |
$9,774 |
I/I |
(200) |
121,253 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-10-01 |
4 |
AS |
$47.75 |
$146,222 |
D/D |
(3,000) |
10,198 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-10-01 |
4 |
OE |
$1.50 |
$4,500 |
D/D |
3,000 |
13,198 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-10-01 |
4 |
AS |
$47.70 |
$136,227 |
I/I |
(2,800) |
121,453 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-09-12 |
4 |
AS |
$50.00 |
$50,000 |
I/I |
(1,000) |
124,253 |
|
- |
|
| Harris William G |
SVP, Finance and CFO |
• – – |
2008-09-02 |
4 |
AS |
$48.74 |
$73,575 |
D/D |
(1,500) |
30,782 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-09-02 |
4 |
AS |
$49.01 |
$147,280 |
I/I |
(3,000) |
125,253 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-09-02 |
4 |
AS |
$48.81 |
$147,208 |
D/D |
(3,000) |
10,198 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-09-02 |
4 |
OE |
$1.50 |
$4,500 |
D/D |
3,000 |
13,198 |
|
- |
|
| Wierenga Wendall D |
Director |
– • – |
2008-08-19 |
4 |
S |
$48.50 |
$194,164 |
D/D |
(4,000) |
3,998 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-08-14 |
4 |
AS |
$49.00 |
$49,000 |
D/D |
(1,000) |
10,198 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-08-14 |
4 |
OE |
$1.50 |
$1,500 |
D/D |
1,000 |
11,198 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-08-14 |
4 |
AS |
$50.00 |
$50,000 |
I/I |
(1,000) |
128,253 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-08-01 |
4 |
AS |
$45.97 |
$23,008 |
I/I |
(500) |
129,253 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-08-01 |
4 |
AS |
$45.63 |
$91,750 |
D/D |
(2,000) |
10,198 |
|
- |
|
| Cundy Kenneth C |
SVP, Preclinical Development |
• – – |
2008-08-01 |
4 |
OE |
$1.50 |
$3,000 |
D/D |
2,000 |
12,198 |
|
- |
|
| Harris William G |
SVP, Finance and CFO |
• – – |
2008-08-01 |
4 |
AS |
$45.64 |
$68,806 |
D/D |
(1,500) |
32,282 |
|
- |
|
| Gallop Mark A |
SVP, Research |
• – – |
2008-08-01 |
4 |
AS |
$45.56 |
$114,540 |
I/I |
(2,500) |
129,753 |
|
- |
|
663 Records found
|
|
Page 17 of 27 |
|
|
